Lv11
40 积分 2024-08-26 加入
Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial
1小时前
待确认
Redefining the Position of Hormonal Therapy in Endometrial Cancer in the Era of Molecular Classification
3个月前
已完结
Manipulating Radiation‐Sensitive Z‐DNA Conformation for Enhanced Radiotherapy
3个月前
已完结
皖公网安备34019202002308
